Skip to content

Study · Measured the body's own peptide · 2025

2 results

Oxytocin levels in response to CRH administration in hypopituitarism and hypothalamic damage: a randomized, crossover, placebo-controlled trial.

Asla Q, Garrido M, Urgell E, Terzan S, Santos A, Fernández M, Varghese N, Atila C, Calabrese A, Biagetti B, Plessow F, Gich I and 5 more

Show all authors

Christ-Crain M, Eckert A, Webb SM, Lawson EA, Aulinas A

Scientific reports18 Jan 2025Cited by 7 (Europe PMC)

PMID39824923 (opens in a new tab)PMCIDPMC11742408 (opens in a new tab)DOI10.1038/s41598-025-86566-y (opens in a new tab)PepBankPUB-39824923
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelRandomized controlled trialOther

    In adults with hypopituitarism and hypothalamic damage and healthy controls, CRH administration did not change the body's own oxytocin concentrations over time (p = 0.97).

    In plain wordsIn adults with pituitary or hypothalamic damage and in healthy adults, CRH did not change the body's own oxytocin levels.

    Peptide
    Oxytocin
    Outcome
    No significant changeOxytocin concentration after CRH versus placebo
    Study

    n = 39

    Comparator
    Placebo
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    p value
    0.97
    CRH effect on oxytocin over time

    Source sentences

    Summary
    CRH administration did not impact oxytocin concentrations across groups over time (p = 0.97).
    1 context sentence
    Summary · context
    Nineteen HHD patients (10 females) and 20 HC (11 females) completed two visits, receiving CRH or placebo in random order and completed validated questionnaires to assess psychopathology, sexual function and QoL.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelRandomized controlled trialOther

    In adults with hypopituitarism and hypothalamic damage and in controls, baseline oxytocin and oxytocin area under the curve were not significantly associated with psychopathology, sexual function or quality of life.

    In plain wordsIn adults with pituitary or hypothalamic damage and in controls, natural oxytocin was not linked to mental health, sexual function or quality of life.

    Peptide
    Oxytocin
    Outcome
    No significant changeBaseline oxytocin and AUC association with psychopathology, sexual function and quality of life
    Study

    n = 39

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    baseline oxytocin concentrations and area under the curve of oxytocin were not significantly associated with psychopathology, sexual function or QoL, neither in HHD or HC
    1 context sentence
    Summary · context
    Nineteen HHD patients (10 females) and 20 HC (11 females) completed two visits, receiving CRH or placebo in random order and completed validated questionnaires to assess psychopathology, sexual function and QoL.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT04902235

Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Paun = 526 Jul 2021 to 1 May 2023

Hypopituitarism · Central Diabetes Insipidus · Panhypopituitarism · Psychological Disorder · Social Isolation · Hypothalamic Diseases · Pituitary Diseases · Oxytocin Deficiency

Trial pageClinicalTrials.govUpdated 3 Apr 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.